[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637367":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":26,"locations":26,"responsibleParty":31,"collaborators":26,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":38,"acronym":26,"eligibilityCriteria":39,"healthyVolunteers":35,"sex":40,"minAge":41,"maxAge":42,"enrollmentInfo":43,"targetDuration":26,"studyType":46,"phases":47,"briefSummary":49,"conditions":50,"keywords":56,"overallStatus":62,"whyStopped":26,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":26},{"fullName":5,"class":6},"Beijing Anzhen Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"GXNT treatment group","EXPERIMENTAL","Immediately after PPCI, the patient was given a loading dose of 4 tablets of Guanxinning Tablets, and then 4 tablets of Guanxinning Tablets were given tid for maintenance treatment, along with standard secondary prevention treatment for coronary heart disease.",[13],"Drug: Guanxinning Tablet(GXNT)",{"label":15,"type":16,"description":17,"interventionNames":18},"standard treatment group","PLACEBO_COMPARATOR","Immediately after PPCI, the patient was given a loading dose of 4 tablets of placebo, and then 4 tablets of placebo were given tid for maintenance treatment, along with standard secondary prevention treatment for coronary heart disease.",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Guanxinning Tablet(GXNT)","Guanxinning Tablets (2015), an established treatment for stable exertional angina (Grades I-II) with TCM-diagnosed heart-blood stasis syndrome, demonstrates proven safety\u002Fefficacy. Its active components (e.g., tanshinone IIA, salvianolic acid B, tetramethylpyrazine) from Salvia miltiorrhiza and Ligusticum chuanxiong exert:\n\nAnti-atherosclerotic effects via:\n\nAnti-inflammation \\& anti-LDL oxidation Endothelial improvement VSMC proliferation\u002Fmigration inhibition Anti-platelet aggregation\n\nMicrovascular protection through:\n\nAnti-apoptosis \\& autophagy regulation Platelet adhesion inhibition Reduced inflammatory factor release",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","In this study, the placebo used in the placebo control group was completely consistent with the Guanxinning Tablets (GXNT) used in the experimental group in terms of appearance, including color, shape, size, gloss, odor, bitterness, dissolution rate, and packaging.",[15],{"type":32,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100637367","phase-2-effect-of-guanxinning-tablet-on-coronary-microcirculation-after-primary-percutaneous-coronary-intervention-in-patients-with-acute-myocardial-infarction-100637367",false,"NCT07621107","Effect of Guanxinning Tablet on Coronary Microcirculation After Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction","A Randomized Explorative Pre-trial of the Effect of Guanxinning Tablet on Coronary Microcirculation After Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction","Inclusion Criteria:\n\n* Age between 18 and 80 years (gender is not restricted).\n* STEMI diagnosed for the first time and with an onset time within 12 hours. (According to the \"Chinese Guidelines for the Diagnosis and Treatment of Acute ST - Segment Elevation Myocardial Infarction 2019\" and the fourth - edition \"Global Definition of Myocardial Infarction\" criteria, myocardial infarction refers to acute myocardial injury \\[serum cardiac troponin (cTn) increases and\u002For decreases, and at least once is higher than the upper limit of the normal value (the 99th percentile of the upper limit of the reference value)\\], along with clinical evidence of acute myocardial ischemia, including: (1) Symptoms of acute myocardial ischemia; (2) New ischemic electrocardiogram changes; (3) New pathological Q - wave; (4) New imaging evidence of viable myocardial loss or abnormal wall segmental motion; (5) Coronary artery thrombosis confirmed by coronary angiography, intracavitary imaging examination, or autopsy.)\n* Successfully received PPCI treatment (assessed by visual inspection or quantitative coronary angiography, with residual stenosis of the target lesion \\\u003C 20% after stent implantation or \\\u003C 50% after simple balloon dilation, and forward TIMI blood flow ≥ grade 2).\n* Signed a written informed consent form.\n\nExclusion Criteria:\n\n* Cardiogenic shock with poor response to vasoactive drugs; or uncontrolled acute left - heart failure or pulmonary edema; uncontrolled malignant arrhythmia.\n* LVEF \\\u003C 40%.\n* Currently using nicorandil, other Chinese patent medicines, and Chinese herbal decoctions, etc.\n* Unable to undergo CMR examination for various reasons.\n* Expected to be unable to complete 6 - month treatment with Guanxinning Tablets.\n* Contraindications or allergies to Guanxinning Tablets.\n* Suspected or confirmed hereditary cardiomyopathy (such as hypertrophic, dilated, obstructive cardiomyopathy, cardiac amyloidosis, hemochromatosis cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, etc.).\n* Active or chronic liver disease.\n* Renal insufficiency (eGFR \\\u003C 60ml\u002Fmin\u002F1.73m²).\n* History of previous cerebral hemorrhage.\n* History of alcohol or drug abuse.\n* Known active infection, or severe hematological, metabolic, or endocrine dysfunction.\n* Patients who have received systemic steroid or cyclosporine treatment in the past 3 months.\n* Active malignant tumor.\n* Life expectancy less than 6 months.\n* Pregnant or lactating women.\n* Already participating in other clinical studies.","ALL","18 Years","80 Years",{"count":44,"type":45},70,"ESTIMATED","INTERVENTIONAL",[48],"PHASE2","①Research objective: In a small sample population, through the pre - experimental method, explore and evaluate the effect of Guanxinning tablets on the coronary microcirculation after primary percutaneous coronary intervention (PPCI) in patients with acute ST - segment elevation myocardial infarction (STEMI), with the change in the percentage of intramyocardial hemorrhage (IMH) in ventricular mass measured by cardiac magnetic resonance (CMR) imaging as the primary endpoint.\n\n②Research significance: The research results of this project will provide preliminary theoretical basis and methodological support for the formal randomized controlled study on evaluating the effect of Guanxinning tablets on the coronary microcirculation after PPCI in STEMI patients. It will offer new ideas for the long - term clinical treatment of STEMI patients after PPCI, and provide important theoretical support for expanding the clinical indications of Guanxinning tablets and exploring the reasons for its improvement of cardiovascular outcomes.",[51,52,53,54,55],"STEMI (ST Elevation MI)","STEMI - ST Elevation Myocardial Infarction","STEMI","CMD","Coronary Microvascular Dysfunction (CMD)",[57,58,59,60,61],"TCM","traditional chinese medicine","guanxinning tablet","CMR","intramyocardial hemorrhage","NOT_YET_RECRUITING","2026-05-27",{"date":65,"type":66},"2026-06-02","ACTUAL",{"date":68,"type":45},"2026-06-01",{"date":70,"type":45},"2027-02-01",{"name":5,"class":6}]